Bristol Myers Squibb Co (BMY): Net Income
$7.05B
Year ended 2025-12-31
$9.28B
Trailing 12 months to 2026-06-30
+3.7%
3-year compound annual growth
+16.2%
10-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.05B | n/m | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | -$8.95B | n/m | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $8.03B | +26.8% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $6.33B | -9.5% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $6.99B | n/m | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | -$9.02B | n/m | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $3.44B | -30.1% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $4.92B | +388.6% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $1.01B | -77.4% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $4.46B | +184.8% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $1.56B | -21.9% | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $2.00B | -21.8% | 2017-02-21, From 2014-01-01 |
| 2013-12-31 | $2.56B | +30.8% | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | $1.96B | -47.2% | 2015-02-13, From 2012-01-01 |
| 2011-12-31 | $3.71B | +19.6% | 2014-02-14, From 2011-01-01 |
| 2010-12-31 | $3.10B | -70.8% | 2013-02-15, From 2010-01-01 |
| 2009-12-31 | $10.61B | +102.2% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $5.25B | +142.4% | 2011-02-18, From 2008-01-01 |
| 2007-12-31 | $2.17B | n/a | 2010-02-19, From 2007-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $4.23B | -1.2% |
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.41B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.50B | +2.1% |
Compare BMY, ABT, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗